Moderna, Inc. (NASDAQ:MRNA) Expected to Earn Q1 2023 Earnings of $1.60 Per Share

Moderna, Inc. (NASDAQ:MRNAGet Rating) – Stock analysts at Jefferies Financial Group decreased their Q1 2023 EPS estimates for shares of Moderna in a research report issued to clients and investors on Wednesday, August 3rd. Jefferies Financial Group analyst M. Yee now expects that the company will post earnings per share of $1.60 for the quarter, down from their previous forecast of $1.76. The consensus estimate for Moderna’s current full-year earnings is $27.29 per share.

Moderna (NASDAQ:MRNAGet Rating) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported $5.24 earnings per share for the quarter, beating the consensus estimate of $4.73 by $0.51. The firm had revenue of $4.73 billion for the quarter, compared to analysts’ expectations of $3.95 billion. Moderna had a net margin of 61.12% and a return on equity of 94.76%. The business’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the company posted $6.46 EPS.

Other analysts have also recently issued research reports about the stock. Morgan Stanley lowered their price objective on shares of Moderna from $199.00 to $197.00 and set an “equal weight” rating on the stock in a research report on Thursday. SVB Leerink raised their price objective on shares of Moderna from $70.00 to $77.00 and gave the company an “underperform” rating in a research report on Monday, August 1st. Finally, Piper Sandler lowered their price objective on shares of Moderna from $348.00 to $214.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 17th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $226.92.

Moderna Stock Performance

Moderna stock opened at $186.84 on Friday. The firm’s fifty day moving average price is $152.33 and its 200-day moving average price is $152.85. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.56 and a current ratio of 1.99. The stock has a market cap of $74.32 billion, a P/E ratio of 5.69, a price-to-earnings-growth ratio of 1.05 and a beta of 1.61. Moderna has a fifty-two week low of $115.61 and a fifty-two week high of $497.49.

Insider Buying and Selling at Moderna

In other Moderna news, President Stephen Hoge sold 234 shares of the business’s stock in a transaction dated Tuesday, May 10th. The shares were sold at an average price of $133.71, for a total value of $31,288.14. Following the transaction, the president now owns 1,622,820 shares in the company, valued at $216,987,262.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Moderna news, President Stephen Hoge sold 234 shares of the business’s stock in a transaction dated Tuesday, May 10th. The shares were sold at an average price of $133.71, for a total value of $31,288.14. Following the transaction, the president now owns 1,622,820 shares in the company, valued at $216,987,262.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Stephane Bancel sold 9,000 shares of the business’s stock in a transaction dated Wednesday, May 11th. The shares were sold at an average price of $127.13, for a total transaction of $1,144,170.00. Following the completion of the transaction, the chief executive officer now owns 5,395,535 shares in the company, valued at approximately $685,934,364.55. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 606,029 shares of company stock worth $91,997,025. 17.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Moderna

A number of large investors have recently modified their holdings of MRNA. Vestmark Advisory Solutions Inc. boosted its stake in shares of Moderna by 108.5% during the 4th quarter. Vestmark Advisory Solutions Inc. now owns 1,084 shares of the company’s stock valued at $275,000 after purchasing an additional 564 shares in the last quarter. D.A. Davidson & CO. boosted its stake in shares of Moderna by 28.9% during the 4th quarter. D.A. Davidson & CO. now owns 7,143 shares of the company’s stock valued at $1,814,000 after purchasing an additional 1,600 shares in the last quarter. CWM LLC bought a new stake in Moderna during the fourth quarter worth about $810,000. Capital Investment Advisory Services LLC boosted its stake in Moderna by 38.0% during the fourth quarter. Capital Investment Advisory Services LLC now owns 998 shares of the company’s stock worth $253,000 after acquiring an additional 275 shares in the last quarter. Finally, AGF Investments Inc. boosted its stake in Moderna by 89.4% during the fourth quarter. AGF Investments Inc. now owns 2,826 shares of the company’s stock worth $718,000 after acquiring an additional 1,334 shares in the last quarter. Institutional investors own 61.20% of the company’s stock.

Moderna Company Profile

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Read More

Earnings History and Estimates for Moderna (NASDAQ:MRNA)

Want More Great Investing Ideas?

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.